PharmaCyte Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMCB research report →
Price Chart
About the company
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites.
- CEO
- Joshua N. Silverman
- IPO
- 2013
- Employees
- 2
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on PMCB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.25M
- P/E
- -0.12
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.10
- EV/EBITDA
- 2.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.44%
- ROIC
- -19.51%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-6,853,713
- Net Income
- $-19,424,654-163.4%
- EPS
- $-52.63-186.8%
- OCF Growth
- -73.0%
- FCF Growth
- -73.0%
- 52W High
- $28.69
- 52W Low
- $3.98
- 50D MA
- $7.15
- 200D MA
- $11.54
- Beta
- 0.68
- RSI (14)
- 25
- Avg Volume
- 14.61K
No earnings-call transcripts are available for PMCB yet.
- Free Float
- 93.8%
- Shares Outstanding
- 565.03K
- Float Shares
- 529.95K
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 140.41K | ▼ 142.97K |
| Geode Capital Management, LLC | 123.93K | ▼ 313 |
| Vanguard Group Inc | 74.92K | 0 |
| Renaissance Technologies LLC | 64.74K | ▲ 26.75K |
| Jane Street Group, LLC | 64.15K | ▲ 34.09K |
| Vanguard Capital Management LLC | 56.78K | 0 |
| Northern Trust Corp | 32.62K | 0 |
| Xtx Topco Ltd | 30.39K | ▼ 3.79K |
| Susquehanna International Group, Llp | 30.06K | ▼ 14.79K |
| Stonex Group Inc. | 30.01K | ▲ 30.01K |
| Schonfeld Strategic Advisors LLC | 26.25K | ▼ 679 |
| Vanguard Fiduciary Trust Co | 23.45K | 0 |
Held by 7 ETFs
Biggest fund positions in PMCB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | WALKER WAYNE REMELL | other | 0 |
| Mar 31, 26 | Abecassis Michael M | other | 0 |
| Mar 31, 26 | SCHECHTER JONATHAN | other | 0 |
| Mar 31, 26 | WEINSTEIN ROBERT | other | 0 |
| Mar 31, 26 | WEINSTEIN ROBERT | other | 119,170 |
| Mar 31, 26 | WALKER WAYNE REMELL | other | 119,170 |
| Mar 31, 26 | SCHECHTER JONATHAN | other | 119,170 |
| Mar 31, 26 | Abecassis Michael M | other | 119,170 |
| Jan 7, 26 | Silverman Joshua | buy | 40,000 |
| Jan 6, 26 | Silverman Joshua | buy | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMCB coverage
Recent articles, reports, and earnings notes.
No research on PMCB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMCB report →PharmaCyte Biotech Reports Strong Cash and Asset Position
businesswire.com · Nov 13
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
businesswire.com · Nov 11
Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why
defenseworld.net · Apr 14
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
defenseworld.net · Dec 5
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
businesswire.com · Nov 25
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
businesswire.com · Aug 20
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
businesswire.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.